- Medicine Name: Portrazza
- Generic Name: Necitumumab
- Dosage Form & Strength: Injection: 800 mg/50 mL (16 mg/mL) solution in a single-dose vial
- Manufactured By: Eli Lilly and Company
Portrazza is an EGFR antagonist approved to be used in conjunction with cisplatin and gemcitabine, for first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC). This medicine is not for the treatment of non-squamous non-small cell lung cancer.
Recommended Dosage: The recommended dosage is 800 mg given as an intravenous (IV) infusion over an hour on Days 1 & 8 of each 3-week cycle before the infusion of gemcitabine and cisplatin. Continue treatment with Portrazza injection until the disease is progressive or unacceptable toxicity occurs.
For those who have previously experienced Grade 1/2 infusion-related reaction (IRR), pre-medicate with diphenhydramine hydrochloride (or equivalent) before all subsequent infusions of Portrazza.
For those who have experienced a second Grade 1/2 occurrence of IRR, pre-medicate for all subsequent infusions, with acetaminophen (or equivalent), diphenhydramine hydrochloride (or equivalent), and dexamethasone (or equivalent) before each infusion of Portrazza
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.